CYTK
Price
$34.50
Change
-$0.75 (-2.13%)
Updated
Aug 8, 02:19 PM (EDT)
Capitalization
4.2B
83 days until earnings call
IMVT
Price
$15.87
Change
+$0.14 (+0.89%)
Updated
Aug 8, 10:40 AM (EDT)
Capitalization
2.69B
84 days until earnings call
Interact to see
Advertisement

CYTK vs IMVT

Header iconCYTK vs IMVT Comparison
Open Charts CYTK vs IMVTBanner chart's image
Cytokinetics
Price$34.50
Change-$0.75 (-2.13%)
Volume$200
Capitalization4.2B
Immunovant
Price$15.87
Change+$0.14 (+0.89%)
Volume$199
Capitalization2.69B
CYTK vs IMVT Comparison Chart in %
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. IMVT commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and IMVT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (CYTK: $35.25 vs. IMVT: $15.73)
Brand notoriety: CYTK and IMVT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 76% vs. IMVT: 53%
Market capitalization -- CYTK: $4.2B vs. IMVT: $2.69B
CYTK [@Biotechnology] is valued at $4.2B. IMVT’s [@Biotechnology] market capitalization is $2.69B. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileIMVT’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • IMVT’s FA Score: 0 green, 5 red.
According to our system of comparison, both CYTK and IMVT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 6 TA indicator(s) are bullish while IMVT’s TA Score has 3 bullish TA indicator(s).

  • CYTK’s TA Score: 6 bullish, 4 bearish.
  • IMVT’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than IMVT.

Price Growth

CYTK (@Biotechnology) experienced а -6.35% price change this week, while IMVT (@Biotechnology) price change was -2.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.10%. For the same industry, the average monthly price growth was +6.25%, and the average quarterly price growth was +12.56%.

Reported Earning Dates

CYTK is expected to report earnings on Oct 30, 2025.

IMVT is expected to report earnings on Oct 31, 2025.

Industries' Descriptions

@Biotechnology (-0.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.2B) has a higher market cap than IMVT($2.69B). CYTK YTD gains are higher at: -25.064 vs. IMVT (-36.496). IMVT has higher annual earnings (EBITDA): -437.78M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. IMVT (714M). IMVT has less debt than CYTK: IMVT (98K) vs CYTK (791M). CYTK has higher revenues than IMVT: CYTK (19.2M) vs IMVT (0).
CYTKIMVTCYTK / IMVT
Capitalization4.2B2.69B156%
EBITDA-513.62M-437.78M117%
Gain YTD-25.064-36.49669%
P/E RatioN/AN/A-
Revenue19.2M0-
Total Cash938M714M131%
Total Debt791M98K807,143%
FUNDAMENTALS RATINGS
CYTK vs IMVT: Fundamental Ratings
CYTK
IMVT
OUTLOOK RATING
1..100
7659
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
41
Fair valued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6063
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
49n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (41) in the null industry is somewhat better than the same rating for CYTK (100) in the Biotechnology industry. This means that IMVT’s stock grew somewhat faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (86) in the Biotechnology industry is in the same range as IMVT (100) in the null industry. This means that CYTK’s stock grew similarly to IMVT’s over the last 12 months.

IMVT's SMR Rating (98) in the null industry is in the same range as CYTK (100) in the Biotechnology industry. This means that IMVT’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (60) in the Biotechnology industry is in the same range as IMVT (63) in the null industry. This means that CYTK’s stock grew similarly to IMVT’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for IMVT (100) in the null industry. This means that CYTK’s stock grew significantly faster than IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKIMVT
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SIDNX12.58N/A
N/A
Hartford Schroders Intl Multi-Cp Val I
PAWAX76.06N/A
N/A
T. Rowe Price All-Cap Opportunities-Adv
ARYGX13.32N/A
N/A
American Century Global Real Estate R5
BGVIX33.44N/A
N/A
Brandes Global Equity I
ECOIX10.61N/A
N/A
Ecofin Global Renewables Infras Ins

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
-1.44%
ROIV - IMVT
53%
Loosely correlated
-0.86%
IDYA - IMVT
51%
Loosely correlated
-5.16%
CYTK - IMVT
50%
Loosely correlated
+0.31%
CGON - IMVT
48%
Loosely correlated
-3.80%
BRNS - IMVT
48%
Loosely correlated
+10.69%
More